Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K


Lucas C. L. , Zhang Y., Venida A., Wang Y., Hughes J., McElwee J., et al.

JOURNAL OF EXPERIMENTAL MEDICINE, cilt.211, ss.2537-2547, 2014 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 211 Konu: 13
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1084/jem.20141759
  • Dergi Adı: JOURNAL OF EXPERIMENTAL MEDICINE
  • Sayfa Sayısı: ss.2537-2547

Özet

Class IA phosphatidylinositol 3-kinases (PI3K), which generate PIP3 as a signal for cell growth and proliferation, exist as an intracellular complex of a catalytic subunit bound to a regulatory subunit. We and others have previously reported that heterozygous mutations in PIK3CD encoding the p110 delta catalytic PI3K subunit cause a unique disorder termed p110 delta activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI) disease. We report four patients from three families with a similar disease who harbor a recently reported heterozygous splice site mutation in PIK3R1, which encodes the p85 alpha, p55 alpha, and p50 alpha regulatory PI3K subunits. These patients suffer from recurrent sinopulmonary infections and lymphoproliferation, exhibit hyperactive PI3K signaling, and have prominent expansion and skewing of peripheral blood CD8(+) T cells toward terminally differentiated senescent effector cells with short telomeres. The PIK3R1 splice site mutation causes skipping of an exon, corresponding to loss of amino acid residues 434-475 in the inter-SH2 domain. The mutant p85. protein is expressed at low levels in patient cells and activates PI3K signaling when overexpressed in T cells from healthy subjects due to qualitative and quantitative binding changes in the p85 alpha-p110 delta complex and failure of the C-terminal region to properly inhibit p110 delta catalytic activity.